The resistance of CML cells to TKI can occur via mechanisms that prevent the inhibition of tyrosine kinase, e.g., drug efflux, overproduction and/or mutation of BCR-ABL [14, 16]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.